Controlled clinical trial of intravenous acyclovir in heart-transplant patients with mucocutaneous herpes simplex infections.
Viral cultures of mucocutaneous herpes simplex lesions became negative in 5 heart-transplant patients given a 7-day course of intravenous acyclovir. Relief of pain and healing of lesions paralleled the virological response. Similar clinical and virological responses were not seen in the 5 placebo-treated patients in this double-blind placebo-controlled trial. No adverse reactions attributable to acyclovir were noted. Shedding of herpes simplex viruses recurred in 3 patients after acyclovir therapy.
D000212:Acyclovir; D000328:Adult; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D006147:Guanine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D016027:Heart Transplantation; D006561:Herpes Simplex / Q000188:drug therapy*; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D011182:Postoperative Care; D011897:Random Allocation; D014184:Transplantation, Homologous
D006147:Guanine; D000212:Acyclovir